Managing Heart Disease and Acute Coronary Syndrome: Latest Treatments and Challenges

What is it about?

This article reviews the current clinical management strategies for coronary artery disease (CAD) and acute coronary syndrome (ACS), highlighting the shared pathophysiological basis of these conditions. It discusses the integration of conventional pharmacological treatments such as aspirin and beta-blockers with emerging therapies like PCSK9 inhibitors and RNA-based treatments. The article identifies significant challenges, including the heterogeneity in patient responses and the debate over the optimal duration of dual antiplatelet therapy. Despite advancements, long-term safety data for newer therapies remain incomplete, posing a challenge for clinical application. The review emphasizes the need for a multidisciplinary approach incorporating lifestyle modifications, interventional procedures, and mechanical circulatory support to optimize patient outcomes. Additionally, it underscores the importance of improving adherence strategies and refining individualized treatment regimens to advance global cardiovascular care.

Featured Image

Why is it important?

This review examines the ongoing challenges and advancements in the management of coronary artery disease (CAD) and acute coronary syndrome (ACS), highlighting the complexity of these cardiovascular conditions. It synthesizes current knowledge and emerging therapies to improve patient outcomes, emphasizing the necessity for a multidisciplinary approach in treatment. The review underscores the global health impact of CAD and ACS, which remain leading causes of mortality, and calls for continued innovation in therapeutic strategies to address persistent clinical challenges. Key Takeaways: 1. This review article summarises the limitations of current pharmacologic and interventional therapies for CAD and ACS, emphasizing the need for individualized treatment plans due to variable patient responses and the ongoing debate over the optimal duration of dual antiplatelet therapy (DAPT). 2. The article highlights emerging therapeutic options, such as proprotein convertase subtilisin kexin type 9 inhibitors, RNA-based therapies, and anti-inflammatory agents, which offer innovative approaches to complement traditional treatments and address their limitations. 3. The review discusses the importance of an interdisciplinary approach in managing atherosclerotic diseases, integrating medical therapy, lifestyle modifications, and interventional procedures to reduce heart attack risk and improve outcomes, while also addressing the challenge of treatment adherence.